Corbus Pharmaceuticals Holdings, Inc. (CRBP)
Corbus Pharmaceuticals Holdings, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in Norwood, MA, US. The stock last traded at $9.51, up 0.53% on the session, giving a market capitalisation of $176.2M. On trailing twelve-month figures it carries a trailing P/E of -1.47, a net margin of 0.0%. Its beta of 2.56 implies it has historically moved more than the broad market.
Corbus Pharmaceuticals Holdings, Inc. is an oncology company, which engages in research, development, and commercializing therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFß expressed on cancer cells, and CRB-913, a highly peripherally restricted cannabinoid type-1 (CB1) receptor inverse agonist for the treatment of obesity. The company was founded in April 2009 and is headquartered in Norwood, MA.
Corbus Pharmaceuticals Holdings, Inc. is most often compared with the following Healthcare names: